MX2021008147A - Polipeptidos que comprenden polipeptidos con il-2 modificada y usos de los mismos. - Google Patents

Polipeptidos que comprenden polipeptidos con il-2 modificada y usos de los mismos.

Info

Publication number
MX2021008147A
MX2021008147A MX2021008147A MX2021008147A MX2021008147A MX 2021008147 A MX2021008147 A MX 2021008147A MX 2021008147 A MX2021008147 A MX 2021008147A MX 2021008147 A MX2021008147 A MX 2021008147A MX 2021008147 A MX2021008147 A MX 2021008147A
Authority
MX
Mexico
Prior art keywords
polypeptides
modified
agonize
polypeptide
bind
Prior art date
Application number
MX2021008147A
Other languages
English (en)
Inventor
Brendan P Eckelman
John C Timmer
Katelyn Mckabe Willis
Florian J Sulzmaier
Bryan R Becklund
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of MX2021008147A publication Critical patent/MX2021008147A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

La presente invención provee polipéptidos que comprenden una IL-2 modificada, en donde la IL-2 modificada tiene una afinidad reducida por el receptor de IL-2R con respecto a la IL-2 de tipo salvaje; en algunas formas de realización, se proveen polipéptidos que comprenden una IL-2 modificada que se unen y agonizan las células T activadas; asimismo se proveen usos de los polipéptidos que comprenden una IL-2 modificada.
MX2021008147A 2019-01-07 2020-01-06 Polipeptidos que comprenden polipeptidos con il-2 modificada y usos de los mismos. MX2021008147A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962789075P 2019-01-07 2019-01-07
PCT/US2020/012296 WO2020146221A1 (en) 2019-01-07 2020-01-06 Polypeptides comprising modified il-2 polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
MX2021008147A true MX2021008147A (es) 2021-08-11

Family

ID=69374426

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008147A MX2021008147A (es) 2019-01-07 2020-01-06 Polipeptidos que comprenden polipeptidos con il-2 modificada y usos de los mismos.

Country Status (15)

Country Link
US (1) US20220089667A1 (es)
EP (1) EP3908596A1 (es)
JP (1) JP2022516557A (es)
KR (1) KR20210113265A (es)
CN (1) CN113924311A (es)
AR (1) AR117770A1 (es)
AU (1) AU2020206672A1 (es)
BR (1) BR112021012294A2 (es)
CA (1) CA3125529A1 (es)
CL (1) CL2021001779A1 (es)
IL (1) IL284633A (es)
MX (1) MX2021008147A (es)
SG (1) SG11202106700WA (es)
TW (1) TW202043259A (es)
WO (1) WO2020146221A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ761430A (en) 2017-08-03 2024-03-22 Synthorx Inc Cytokine conjugates for the treatment of proliferative and infectious diseases
CN115710576A (zh) 2018-02-01 2023-02-24 Nkmax有限公司 产生天然杀伤细胞的方法和用于治疗癌症的组合物
KR102313505B1 (ko) * 2020-06-30 2021-10-18 (주)지아이이노베이션 항-lag-3 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
WO2022006380A2 (en) * 2020-07-02 2022-01-06 Inhibrx, Inc. Polypeptides comprising modified il-2 polypeptides and uses thereof
CN112979782B (zh) * 2021-03-08 2023-07-18 深圳市乐土生物医药有限公司 一种多肽及其用途
WO2022212614A1 (en) * 2021-03-31 2022-10-06 Anwita Biosciences, Inc. Fusion proteins, pharmaceutical compositions, and therapeutic applications
WO2023004304A1 (en) * 2021-07-20 2023-01-26 Inhibrx, Inc. Cd8-binding polypeptides and uses thereof
TW202309102A (zh) * 2021-07-20 2023-03-01 美商英伊布里克斯公司 靶向cd8之經修飾il-2多肽及其用途
TW202328171A (zh) * 2021-08-30 2023-07-16 美商英伊布里克斯公司 靶向NKp46之經修飾之IL-2多肽及其用途
CA3228815A1 (en) * 2021-08-30 2023-03-09 John C. Timmer Nkp46-binding polypeptides and uses thereof
WO2023046156A1 (en) * 2021-09-26 2023-03-30 Wuxi Biologics (Shanghai) Co. Ltd. Il-2 variants and fusion proteins thereof
TW202334193A (zh) * 2022-01-05 2023-09-01 美商英伊布里克斯公司 靶向γδ T細胞之經修飾IL-2多肽及其用途
WO2024026449A2 (en) * 2022-07-28 2024-02-01 Proviva Therapeutics (Hong Kong) Limited Il-2 procytokine antibody fusion proteins

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
ATE531812T1 (de) 1997-12-05 2011-11-15 Scripps Research Inst Humanisierung von nager-antikörpern
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
SI1678314T1 (sl) 2003-10-22 2013-01-31 Keck Graduate Institute Metode za sintetiziranje heteromultimernih polipeptidov pri kvasovkah s strategijo razmnoĺ˝evanja haploidnih celic
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
JP2007527242A (ja) * 2004-03-05 2007-09-27 カイロン コーポレーション 治療剤の患者耐容性を予測するためのインビトロ試験システム
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
CN102101885B (zh) * 2010-09-01 2013-06-05 南京发士达生物科技有限公司 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
PE20140303A1 (es) * 2011-02-10 2014-03-22 Roche Glycart Ag Polipeptidos interleuquina-2 mutantes
MX370283B (es) * 2014-02-06 2019-12-09 Hoffmann La Roche Proteinas de fusion de interleucina-2 y usos de las mismas.
KR20180133198A (ko) * 2016-05-04 2018-12-13 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
BR112019024127A2 (pt) * 2017-05-24 2020-06-23 Pandion Therapeutics, Inc. Imunotolerância alvejada

Also Published As

Publication number Publication date
IL284633A (en) 2021-08-31
BR112021012294A2 (pt) 2021-09-08
WO2020146221A1 (en) 2020-07-16
JP2022516557A (ja) 2022-02-28
CA3125529A1 (en) 2020-07-16
US20220089667A1 (en) 2022-03-24
TW202043259A (zh) 2020-12-01
KR20210113265A (ko) 2021-09-15
AU2020206672A1 (en) 2021-07-15
SG11202106700WA (en) 2021-07-29
CL2021001779A1 (es) 2022-03-04
AR117770A1 (es) 2021-08-25
CN113924311A (zh) 2022-01-11
EP3908596A1 (en) 2021-11-17

Similar Documents

Publication Publication Date Title
MX2021008147A (es) Polipeptidos que comprenden polipeptidos con il-2 modificada y usos de los mismos.
MX2022016532A (es) Polipeptidos que comprenden polipeptidos de il-2 modificados y usos de los mismos.
WO2020092854A3 (en) Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
MX2020002596A (es) Polipeptidos moduladores de linfocitos t multimericos y metodos de uso de estos.
MX2017012805A (es) Complejo de unión a antígenos con actividad agonista y métodos de uso.
PH12019550147A1 (en) Engineered transferrin receptor binding polypeptides
GEP20237480B (en) Antibodies against signal-regulatory protein alpha and methods of use
MX2011012184A (es) Polipeptidos bifuncionales.
PH12019502273A1 (en) Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
MA40609B1 (fr) Agents de liaison cd123 et leurs utilisations
NZ756224A (en) Polypeptide variants and uses thereof
MX2009008230A (es) Epitopes de celulas t reguladoras, composiciones y usos para los mismos.
MX2015014017A (es) Variante de la region fc.
WO2020160156A3 (en) Anti-gal3 antibodies and uses thereof
MY187827A (en) New polypeptide having affinity to pd-l1
EP3787080A4 (en) FUEL CELL CATALYST, MEMBRANE ELECTRODE ARRANGEMENT FOR FUEL CELL AND FUEL CELL WITH IT
AU2019321490A8 (en) Ox40-binding polypeptides and uses thereof
EP3835320A4 (en) BINDING OF CHEMERA ANTIGEN RECEPTOR TO HLA-DR, AND CAR-T CELL
WO2011056954A3 (en) Haemophilus parasuis polypeptides and methods of use
BR112019013005A2 (pt) espécie de metschnikowia isolada, método para produzir xilitol, xilitol bioderivado e composição
MX2022012541A (es) Inmunoconjugados.
EP3672724A4 (en) ELECTRIC CATALYSTS, THEIR PRODUCTION AND USE FOR FUEL CELLS
MX2022013840A (es) Polipéptidos de unión a pd-1 canina y usos de los mismos.
WO2020235974A3 (ko) 단일염기 치환 단백질 및 이를 포함하는 조성물
EP3767723A4 (en) ELECTRODE CATALYST FOR FUEL CELL AND FUEL CELL WITH USE THEREOF